KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.
Saved in:
| Title: | KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer. |
|---|---|
| Authors: | Bambach NE; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Ricarte-Filho JC; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Reichenberger ER; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Hernandez-Padilla C; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Hinkle K; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Isaza A; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Bauer AJ; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States., Franco AT; Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States.; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jan 07; Vol. 15, pp. 1685379. Date of Electronic Publication: 2026 Jan 07 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1685379 |
